MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs

Science Advances

Volumn 1, Issue 9, 2015, Pages

  Wang, Lu ^a   Zeng, Hao ^a,b   Wang, Qiang ^a,c,d   Zhao, Zibo ^a   Boyer, Thomas G ^e   Bian, Xiuwu ^c,d   Xu, Wei ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; AMINO ACIDS; CELL CULTURE; CHEMICAL ACTIVATION; DIAGNOSIS; DISEASES; DRUG THERAPY; METHYLATION; PATIENT MONITORING; PATIENT TREATMENT;

DRUG RESISTANCE; EXPRESSION LEVELS; HUMAN BREAST CANCER; HUMAN BREAST CANCER CELLS; MEDIATOR COMPLEX; METHYLTRANSFERASES; RNA POLYMERASE II; TRANSFORMING GROWTH FACTOR-B;

CHEMOTHERAPY;

EID: 84991360749     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1500463     Document Type: Article

References (36)

1. M. T. Bedford, S. G. Clarke, Protein arginine methylation in mammals: Who, what, and why. Mol. Cell 33, 1-13 (2009).
2. H. Cheng, Y. Qin, H. Fan, P. Su, X. Zhang, H. Zhang, G. Zhou, Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn. Pathol. 8, 129 (2013).
3. L. Wang, Z. Zhao, M. B. Meyer, S. Saha, M. Yu, A. Guo, K. B. Wisinski, W. Huang, W. Cai, J. W. Pike, M. Yuan, P. Ahlquist, W. Xu, CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell 25, 21-36 (2014).
4. B. A. Lewis, D. Reinberg, The mediator coactivator complex: Functional and physical roles in transcriptional regulation. J. Cell Sci. 116, 3667-3675 (2003).
5. C. Schiano, A. Casamassimi, M. Rienzo, F. de Nigris, I. Sommese, C. Napoli, Involvement of mediator complex in malignancy. Biochim. Biophys. Acta 1845, 66-83 (2014).
6. J. M. Graham Jr., C. E. Schwartz, MED12 related disorders. Am. J. Med. Genet. A 161, 2734-2740 (2013).
7. M. Turunen, J. M. Spaeth, S. Keskitalo, M. J. Park, T. Kivioja, A. D. Clark, N. Mäkinen, F. Gao, K. Palin, H. Nurkkala, A. Vähärautio, M. Aavikko, K. Kämpjärvi, P. Vahteriso, C. A. Kim, L. A. Aaltonen, M. Varjosalo, J. Taipale, T. G. Boyer, Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep. 7, 654-660 (2014).
8. C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J.-P. Theurillat, T. A. White, P. Stojanov, E. Vsn Allen, N. Stansky, E. Nickerson, S.-S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin, L. A. Garraway, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
9. W. K. Lim, C. K. Ong, J. Tan, A. A. Thike, C. C. Y. Ng, V. Rajasegaran, S. S. Myint, S. Nagarajan, N.D.M. Nasir, J.R. McPherson, I. Cutcutache, G. Poore, S.T. Tay, W.S. Ooi, V.K.M. Tan, M. Hartman, K. W. Ong, B. K. T. Tan, S. G. Rozen, P. H. Tan, P. Tan, B. T. Teh, Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat. Genet. 46, 877-880 (2014).
10. S. Huang, M. Hölzel, T. Knijnenburg, A. Schlicker, P. Poepman, U. McDermott, M. Garnett, W. Grernrum, C. Sun, A. Prahallad, F. H. Groenendijik, l. Mittempergher, W. Nijkamp, J. Neefjes, R. Salazar, P. t. Dijke, H. Uramoto, F. Tanaka, R. L. Beijersbergen, L. F. A. Wessels, R. Bernards, MED12 controls the response to multiple cancer drugs through regulation of TGF-b receptor signaling. Cell 151, 937-950 (2012).
11. O. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
12. N. Ding, H. Zhou, P.-O. Esteve, H. G. Chin, S. Kim, X. Xu, S. M. Joseph, M. J. Friez, C. E. Schwartz, S. Pradhan, T. G. Boyer, Mediator links epigenetic silencing of neuronal gene expression with x-linked mental retardation. Mol. Cell 31, 347-359 (2008).
13. S. De, R. Cipriano, M. W. Jackson, G. R. Stark, Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res. 69, 8035-8042 (2009).
14. M. H. Tan, S. De, G. Bebek, M. S. Orloff, R. Wesolowski, E. Downs-Kelly, G. T. Budd, G. R. Stark, C. Eng, Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res. Treat. 131, 849-858 (2012).
15. C. A. Sherman-Baust, K. G. Becker, W. H. Wood III, Y. Zhang, P. J. Morin, Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J. Ovarian Res. 4, 21 (2011).
16. G. J. Kitange, B. L. Carlson, M. A. Schroeder, P. A. Decker, B. W. Morlan, W. Wu, K. V. Ballman, C. Giannini, J. N. Sarkaria, Expression of CD74 in high grade gliomas: A potential role in temozolomide resistance. J. Neuro-Oncol. 100, 177-186 (2010).
17. H. Törma, Regulation of keratin expression by retinoids. Dermatoendocrinol. 3, 136-140 (2011).
18. W. Zhang, S. M. Kornblau, T. Kobayashi, A. Gambel, D. Claxton, A. B. Deisseroth, High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelog-enous leukemia. Clin. Cancer Res. 1, 1051-1057 (1995).
19. M. H. Kagey, J. J. Newman, S. Bilodeau, Y. Zhan, D. A. Orlando, N. L. van Berkum, C. C. Ebmeier, J. Goossens, P. B. Rahl, S. S. Levine, D. J. Taatjes, J. Dekker, R. A. Young, Mediator and cohesin connect gene expression and chromatin architecture. Nature 472, 247 (2011).
20. Y.-H. Lee, M. R. Stallcup, Roles of protein arginine methylation in DNA damage signaling pathways. Is CARM1 a life-or-death decision point? Cell Cycle 10, 1343-1344 (2011).
21. N. Wagle, E. M. Van Allen, D. J. Treacy, D. T. Frederick, Z. A. Cooper, A. Taylor-Weiner, M. Rosenberg, E. M. Goetz, R. J. Sullivan, D. N. Farlow, D. C. Friedrich, K. Anderka, D. Perrin, C. M. Johannessen, A. McKenna, K. Cibulskis, G. Kryukov, E. Hodis, D. P. Lawrence, S. Fisher, G. Getz, S. B. Gabriel, S. L. Carter, K. T. Flaherty, J. A. Wargo, L. A. Garraway, MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68 (2014).
22. R. Firestein, A. J. Bass, S. Y. Kim, I. F. Dunn, S. J. Silver, I. Guney, E. Freed, A. H. Ligon, N. Vena, S. Ogino, M. G. Chheda, P. Tamayo, S. Finn, Y. Shrestha, J. S. Boehm, S. Jain, E. Bojarski, C. Mermel, J. Barretina, J. A. Chan, J. Baselga, J. Tabernero, D. E. Root, C. S. Fuchs, M. Loda, R. A. Shivdasani, M. Meyerson, W. C. Hahn, CDK8 is a colorectal cancer oncogene that regulates b-catenin activity. Nature 455, 547-551 (2008).
23. M. D. Galbraith, M. A. Allen, C. L. Bensard, X. Wang, M. K. Schwinn, B. Qin, H. W. Long, D. L. Daniels, W. C. Hahn, R. D. Dowell, J. M. Espinosa, HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell 153, 1327-1339 (2013).
24. M. T. Knuesel, K. D. Meyer, C. Bernecky, D. J. Taatjes, The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev. 23, 439-451 (2009).
25. M. T. Knuesel, K. D. Meyer, A. J. Donner, J. M. Espinosa, D. J. Taatjes, The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function inde-pendently of mediator. Mol. Cell. Biol. 29, 650-661 (2009).
26. M. J. Rau, S. Fischer, C. J. Neumann, Zebrafish Trap230/Med12 is required as a coactivator for Sox9-dependent neural crest, cartilage and ear development. Dev. Biol. 296, 83-93 (2006).
27. S. Kim, X. Xu, A. Hecht, T. G. Boyer, Mediator is a transducer of Wnt/b-catenin signaling. J. Biol. Chem. 281, 14066-14075 (2006).
28. H. Zhou, S. Kim, S. Ishii, T. G. Boyer, Mediator modulates Gli3-dependent sonic hedgehog signaling. Mol. Cell. Biol. 26, 8667-8682 (2006).
29. X. Xu, H. Zhou, T. G. Boyer, Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling. EMBO Rep. 12, 216-222 (2011).
30. H. Izawa, H. Yamamoto, B. Damdinsuren, K. Ikeda, M. Tsujie, R. Suzuki, K. Kitani, Y. Seki, T. Hayashi, I. Takemasa, M. Ikeda, M. Ohue, M. Sekimoto, T. Monden, M. Monden, Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells. Int. J. Oncol. 27, 69-76 (2005).
31. S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark, C. Namgyal, T. Kawasaki, K. Kinsella, A. L. Michelini, P. C. Enzinger, M. H. Kulke, D. P. Ryan, M. Loda, C. S. Fuchs, Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin. Cancer Res. 11, 6650-6656 (2005).
32. N. Oshimori, D. Oristian, E. Fuchs, TGF-b promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963-976 (2015).
33. Y. Zhang, L. Geng, G. Talmon, J. Wang, MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J. Biol. Chem. 290, 6215-6225 (2015).
34. L. Wang, P. Charoensuksai, N. J. Watson, X. Wang, Z. Zhao, C. G. Coriano, L. R. Kerr, W. Xu, CARM1 automethylation is controlled at the level of alternative splicing. Nucleic Acids Res. 41, 6870-6880 (2013).
35. J. Wu, W. Xu, Histone H3R17me2a mark recruits human RNA polymerase-associated factor 1 complex to activate transcription. Proc. Natl. Acad. Sci. U.S.A. 109, 5675-5680 (2012).
36. Y. S. DeRose, G. Wang, Y.-C. Lin, P. S. Bernard, S. S. Buys, M. T. W. Ebbert, R. Factor, C. Matsen, B. A. Milash, E. Nelson, L. Neumayer, R. L. Randall, I. J. Stijleman, B. E. Welm, A. L. Welm, Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520 (2011).